Lou Gehrig’s disease

Meredith Jackrel, assistant professor of chemistry in Arts & Sciences, recently received a five-year grant from the National Institutes of Health (NIH) and another from the Longer Life Foundation to study protein disaggregases —  evolved protein forms that mitigate protein misfolding — as a strategy to combat neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS.

Genetic mutations may cause more cases of amyotrophic lateral sclerosis (ALS) than scientists previously had realized, according to researchers. Shown are study authors Janet Cady, a PhD candidate, and Matthew Harms, MD, assistant professor of neurology at the School of Medicine.

Digoxin, a medication that has been used to treat heart failure, may be adaptable for the treatment of amyotrophic lateral sclerosis (ALS), a progressive, paralyzing disease, suggests new research at the School of Medicine.

An investigational treatment for an inherited form of Lou Gehrig’s disease has passed an early phase clinical trial for safety, researchers at the School of Medicine and Massachusetts General Hospital report. A mutated protein that causes an inherited form of Lou Gehrig’s disease leads to clumps in the human cells, which are pictured.